BioSig (BSGM) and Its NeuroClear Subsidiary Are Leading the Way in Bioelectric Medicine with Amazing Potential
Good day everyone,
We are updating our coverage on BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace.
Current price $4.12 per share
Outstanding shares (est.) 32.1M
Shares in float (est.) 27.6M
Insider ownership 16.23%
Institutional ownership 18.8%
52-week high $9.77/share
The last time we reported on BSGM was in January of this year and we wanted to update you because a lot has happened in bringing their lead product to market and the company shares seem priced at a value. In addition, the company is developing new disruptive treatments utilizing the nervous system signals for certain indications.
Looking at the company stock chart we see that BSGM shares are above their 50 DMA of $3.50 and below their 200 DMA of $4.40/share.
If you’re not familiar with the BioSig PURE EP technology, it’s an advanced monitoring system currently used primarily for cardiac ablation procedures in patients with AFIB (atrial fibrillation) a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. At least 2.7 million Americans are living with AFib.
The company has begun to generate revenues from the PURE EP System. In April of this year BSGM introduced new software to guide the PURE EP system, incorporating feedback from doctors who have used it.
The company has been appearing at many cardiac conference events since the software upgrade giving PURE EP exposure to the professionals that could benefit from it. We anticipate the activity by the company in 2021, in addition to the new software release could generate new revenues for the company.
More than 940 patient cases have been conducted using the PURE EP™ System by 52 physicians in nine clinical sites to date.
What we really like about BSGM is that they are a pioneer in the field of bioelectric medicine with potential applications across various disease areas and disciplines, including neurology, auto-immune diseases, diabetes, arthritis, hypertension, pain management, cancer, and others.
Bioelectronic medicine is already a diverse, $20 billion market that includes familiar devices, such as pacemakers, as well as emerging technologies, such as vagus nerve stimulators and implantable neurostimulators.
Verily Life Sciences, Medtronic, and Johnson & Johnson are all making investments in bioelectric medicine and BSGM may benefit due to their unique technology providing more precise biomedical signals, and advanced signal processing capabilities.
NeuroClear (a BSGM majority owned subsidiary) and N-Sense
“Our nerves are constantly sending signals to every part of our bodies. What we need to do is listen to these signals and find a way to stimulate desired areas of indication.”– Ken Londoner, Chairman and CEO, NeuroClear (and Biosig).
N-Sense has conducted its first pre-clinical studies and was recently awarded the first patent exclusively licensed from the Mayo Foundation foe Medical Education and Research. The NeuroClear™ division is developing a novel nerve sensing and stimulation technology (N-Sense) to improve current treatments for resistant hypertension and other nerve-related therapeutic targets.
The science being developed at NeuroClear is different from anything we’ve looked at before and if it turns out to be viable, it could disrupt standards of care for many indications. This new concept of sending stimulation through the nervous system to treat nerve sensitive conditions could be the forefront of new medicine and BSGM is a pioneer in the sector. We include a short video about NeuroClear at this link. https://youtu.be/SECSQOrgAHA
BioSig’s patent portfolio, includes nine allowed/issued patents. Sixteen additional worldwide utility patent applications that are pending covering various aspects of its PURE EP™ System. The Company has two additional pending U.S. patent applications directed to artificial intelligence (AI). BioSig has 24 allowed/issued worldwide design patents covering various features of its display screens and graphical user interface for enhanced visualization of biomedical signals. BioSig has exclusive licenses to 15 additional worldwide utility patent applications from Mayo Foundation for Medical Education and Research that are pending. These 15 applications are generally directed to electroporation and stimulation.
BSGM is revolutionizing the way we treat certain cardiac indications with their PURE EP system, and we believe 2021 may bring some decent revenues for that technology. The NeuroClear concept of treating ailments through nervous system stimulation is the stuff the future is made of. Let’s remember that the Mayo Clinic/Foundation, one of the top medical centers in the world, has been a collaborator/partner with BioSig through the development of PURE EP and NeuroClear. The University of Minnesota is also a partner in the development of N-Sense.
The amazing technology being developed at BSGM is likely to garner the interest of investors as well as others in the bioelectric medicine sector.
Stay tuned and stay informed,
The Traders News Group
Do we disclose any information to outside parties?
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.